| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0009-9236(99)70033-0 |
| P698 | PubMed publication ID | 10511061 |
| P2093 | author name string | Tanaka M | |
| Ikeda Y | |||
| Murayama N | |||
| Fujita M | |||
| Inoue T | |||
| Yamada H | |||
| Terada Y | |||
| Kunitada S | |||
| P2860 | cites work | Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery | Q39638109 |
| Proposed cation-pi mediated binding by factor Xa: a novel enzymatic mechanism for molecular recognition. | Q40467984 | ||
| Pharmacokinetic optimisation of the treatment of deep vein thrombosis | Q40905445 | ||
| The kinetics of heparin | Q45182386 | ||
| Dibasic (Amidinoaryl)propanoic Acid Derivatives as Novel Blood Coagulation Factor Xa Inhibitors | Q57310719 | ||
| Prophylaxis of venous thromboembolism: analysis of cost effectiveness | Q71496485 | ||
| Radioimmunoassay method for DX-9065a, an anticoagulant agent. Development, evaluation and application to human plasma | Q71699308 | ||
| Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association | Q72285059 | ||
| A novel factor Xa inhibitor: structure-activity relationships and selectivity between factor Xa and thrombin | Q72673525 | ||
| High-performance liquid chromatographic method for determination of DX-9065a, a novel anticoagulant, in human urine and feces using cation-exchange solid-phase extraction | Q73428173 | ||
| Crystal structures of factor Xa specific inhibitors in complex with trypsin: structural grounds for inhibition of factor Xa and selectivity against thrombin | Q27729322 | ||
| X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition | Q27734011 | ||
| P433 | issue | 3 | |
| P921 | main subject | pharmacodynamics | Q725307 |
| anticoagulant | Q215118 | ||
| pharmacokinetics | Q323936 | ||
| P304 | page(s) | 258-264 | |
| P577 | publication date | 1999-09-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers | |
| P478 | volume | 66 |
| Q34189338 | Anticoagulants and inhibitors of platelet aggregation derived from leeches. |
| Q27000967 | Clinical utility of rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation - patient considerations |
| Q34126365 | Contribution of in vivo models of thrombosis to the discovery and development of novel antithrombotic agents. |
| Q44228251 | Development and validation of a liquid chromatography-mass spectrometric method for the determination of DPC 423, an antithrombotic agent, in rat and dog plasma |
| Q30924299 | Discovery of 3-amino-4-chlorophenyl P1 as a novel and potent benzamidine mimic via solid-phase synthesis of an isoxazoline library |
| Q28477868 | Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation |
| Q36042279 | New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin |
| Q35752611 | New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q34027530 | Novel inhibitors of factor X for use in cardiovascular diseases |
| Q47583481 | Pharmacokinetics of YM466, a new factor Xa inhibitor, in rats and dogs. |
| Q93935767 | Pharmacokinetics of the anticoagulant 14C-DX-9065a in the healthy male volunteer after a single intravenous dose |
| Q35160253 | Selective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery |
| Q36520745 | The status of new anticoagulants |
Search more.